Kasperska-Zajac Alicja, Rogala Barbara
Chair and Clinical Department of Internal Diseases, Allergology and Clinical Immunology, Medical University of Silesia, Katowice, Poland.
Inflammation. 2005 Apr;29(2-3):90-3. doi: 10.1007/s10753-006-9004-0.
Accumulating evidence has indicated that different immune and inflammatory processes may be accompanied by up-regulation of the uPA/uPAR system. Moreover, it has been suggested that the fibrinolytic system participates actively in immune-mediated skin disorders, including atopic eczema/dermatitis syndrome (AEDS). To study a possible role of such uPA/uPAR system in AEDS, we investigated circulating levels of uPA and suPAR in patients at different clinical stages of AEDS. Levels of u-PA and suPAR were measured by enzyme-linked immunoassay in plasma from 13 patients (five females and eight males; median age 27 years) with moderate AEDS, eight patients (three females and five males; median age 25.5 years) with severe AEDS, and 18 age- and sex-matched healthy subjects. Plasma levels of uPA and suPAR in AEDS patients did not differ significantly when compared with those in healthy subjects. Moreover, we failed to observe any significant differences in levels of these components between patients with moderate and severe AEDS and the controls. It seems that plasma levels of uPA and suPAR are similar in patients at the different stages of AEDS and the healthy subjects. Moreover, these data suggest that the release of uPA and its soluble receptor into the bloodstream is not increased in the course of complex immune-mediated processes associated with AEDS.
越来越多的证据表明，不同的免疫和炎症过程可能伴随着尿激酶型纤溶酶原激活物（uPA）/尿激酶型纤溶酶原激活物受体（uPAR）系统的上调。此外，有人提出纤维蛋白溶解系统积极参与免疫介导的皮肤疾病，包括特应性湿疹/皮炎综合征（AEDS）。为了研究这种uPA/uPAR系统在AEDS中可能的作用，我们调查了AEDS不同临床阶段患者血浆中uPA和可溶性尿激酶型纤溶酶原激活物受体（suPAR）的水平。采用酶联免疫吸附测定法检测了13例中度AEDS患者（5名女性和8名男性；中位年龄27岁）、8例重度AEDS患者（3名女性和5名男性；中位年龄25.5岁）以及18名年龄和性别匹配的健康受试者血浆中的uPA和suPAR水平。与健康受试者相比，AEDS患者血浆中uPA和suPAR水平无显著差异。此外，我们未能观察到中度和重度AEDS患者与对照组之间这些成分水平的任何显著差异。似乎在AEDS不同阶段的患者和健康受试者中，血浆中uPA和suPAR水平相似。此外，这些数据表明，在与AEDS相关的复杂免疫介导过程中，uPA及其可溶性受体释放到血液中的量并未增加。
